CLINICAL_TRIALS
trial_result
· 2018-01-02
Clinical Trial Update: Staccato Loxapine in Agitation (Proof of Concept) [Phase 2]
Summary
Phase 2 proof-of-concept trial assessing Staccato Loxapine for agitation in schizophrenia has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alexza Pharmaceuticals, Inc. | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2018-01-02